Genmab — Februar 2018

[E_L]

whiich is a shame for Genmab offcourse as it makes the combo so expensive

[Solsen]

I think they try in short term to keep dara from the market as revlimid is more know and acceptet by now. To buy the combo is a hurdle for both pts and inssurance when CELG dramatically raise pricing.

[E_L]

I hadn't thought of that... do you know the price difference between Revlimid and Pomalidomide? Someone suggested the Dara/Pom/Dex combo could gain significance / compete
in the US based on price

[Solsen]

Read that pom are priced $200.000 annually.

[Solsen]

...and Revlimid $165.000 annually

[E_L]

ok, so that doesnt makes sense then...

[JohnW]

I guess a higher price on Revlimid will be an advantage for selling Alcyone then.

[Teller]

Hello, I am new to this chat, but I have been following it for more than a year now.

[Bulder]

Yes, or the US-equivalent to VMp: CyBorD

[Teller]

Maybe the higher price simply reflects a higher demand?

[Bulder]

The higher the Rev-price goes, the more important is the Dara+CyborD-study, from which we should see data soon.

[Teller]

Solsen - Hvilken dosis (stand alone eller combo) er denne aarlige behandlingspris baseret paa?

[E_L]

how much does
CyborD cost?

[Bulder]

The only drug of the three still patented is bor (Velcade), and it will run out of patent in Europe next year.

[Bulder]

One unit is DKK 10.051 https://min.medicin.dk/Medicin/Praeparater/3370

[Teller]

Hvis der anvendes lavere dosis i combo behandling med dara, bliver det vel ikke noedvendigvis mere omkosteligt at behandle. (ud over de +20% om aaret som mere eller mindre er normalen)

[Teller]

(www.chicagotribune.com)

[Bulder]

Later this year we

[Bulder]

... we'll have data from the Cassiopeia study with thalidomide in stead of lenalidomide. So no wonder Celgene raises prices before it's too late.

[Solsen]

Yes thats what it is. Short CELG